Skip to search formSkip to main contentSkip to account menu

MEK Inhibitor WX-554

Known as: WX-554 
An orally available small molecule mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK) inhibitor, with potential antineoplastic… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037
PurposeTumours frequently have defects in multiple oncogenic pathways, e.g. MAPK and PI3K signalling pathways, and combinations… 
2016
2016
A Phase I pharmacokinetic and pharmacodynamic study of the oral MEK inhibitor , WX-554 , in patients with advanced solid tumours
a. Northern Institute for Cancer Research, Paul O’Gorman Building, Medical School, Newcastle University, Newcastle upon Tyne, NE2… 
2010
2010
A phase I, first-in-human single ascending dose study of the MEK inhibitor WX-554 given to healthy male subjects.
e13666 Background: WX-554 is a small molecule inhibitor targeting mitogen-activated protein kinase kinase (MEK1 and MEK2). The… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)